NEWS & PERSPECTIVES

Psychedelics News

Curated updates on microdosing, research, policy, and community.

The latest

2026-08-21 • The Microdose (Berkeley)

What is an “embedded” brain? Johnson & Johnson plans to invest in “neuroplastogen” company Delix; and University of Miami gifts Trump Administration accelerated path to research ibogaine

Plus: Oregon psilocybin program “generally safe,” according to new study, and New Mexico begins accepting psilocybin producer applications

2026-08-21 • Psychedelic Alpha

Field Notes #4: Resilient Refiles, Definium’s Readout, HRSA’s RFI Responses, and J&J’s Neuroplastogen Bet

Welcome to our fourth Field Note. As a reminder, Field Notes are timely, candid voice notes from our Founder and Editor, Josh Hardman, that give our Pα+ readers a pulse on recent developments in psychedelic drug devel...

2026-08-21 • Medical Xpress (Psychedelics)

More than 2,300 psilocybin users report real-world outcomes in Oregon and Colorado

Over the past few decades, some psychiatrists and medical researchers have been running controlled clinical trials to assess the potential therapeutic value of psychedelics, substances that alter perception, mood and ...

2026-08-21 • The Psychedelic Blog (Substack)

5 Psychedelic Stories You Should Know This Week

Welcome to The Psychedelic Blog. Bestselling essayist & Psychedelic cultural analyst examining how altered states shape relationships, grief, death & meaning.

2026-08-21 • Blossom Pulse

Appetite measures during ketamine administration in treatment-resistant mood disorders: a naturalistic study

This naturalistic study of adult inpatients with treatment-resistant depression or bipolar disorder found that repeated ketamine treatment caused no significant short-term changes in appetite, hunger, or desire to eat...

2026-08-21 • Blossom Pulse: Papers

Appetite measures during ketamine administration in treatment-resistant mood disorders: a naturalistic study

This naturalistic study of adult inpatients with treatment-resistant depression or bipolar disorder found that repeated ketamine treatment caused no significant short-term changes in appetite, hunger, or desire to eat...

2026-08-20 • Psychedelic Passage

Psychedelic Passage Community Member Spotlight: Leah B

This special edition of our podcast series welcomes one of our community members and Psychedelic Passage program participant, Leah B, to sit down with our community steward, Bree, to discuss her own personal healing j...

2026-08-20 • Psychedelic Alpha

Credentials, Clinics, and Costs: Stakeholders Respond to HRSA’s Psychedelic Therapy RFI

The U.S. Health Resources and Services Administration (HRSA) has received 59 comments in response to its request for information (RFI) regarding ‘training and care delivery models for safe administration of potential ...

2026-08-20 • Psychedelic Press (Substack)

Orchidaceaen Ethics 1

On acid, ancient philosophy, and the problem of knowing

2026-08-20 • Blossom Pulse

KetCRPS-2 (2024-511877-31-00, esketamine)

This Phase IV interventional trial (n=60) evaluated whether repeated intravenous esketamine infusions provide non-inferior pain relief to continuous esketamine administration in adults with complex regional pain syndr...

2026-08-20 • Blossom Pulse

HRSA received 59 comments on training and care delivery models for safely administering potential FDA-approved psychedelic therapies in ambulatory settings.

The U.S. Health Resources and Services Administration issued its request for information on 14 July, with submissions closing on 13 August. Responses covered workforce training, delivery through community and rural cl...

2026-08-20 • Blossom Pulse: Papers

Low-dose lysergic acid diethylamide alters subjective visual perception but not visual contrast surround suppression

This randomised, double-blind, within-subjects crossover study (n=30) found that low-dose LSD (10 or 20 μg) changed participants’ subjective visual experiences, making vision seem blurrier, more saturated and more dyn...

2026-08-20 • Blossom Pulse

Low-dose lysergic acid diethylamide alters subjective visual perception but not visual contrast surround suppression

This randomised, double-blind, within-subjects crossover study (n=30) found that low-dose LSD (10 or 20 μg) changed participants’ subjective visual experiences, making vision seem blurrier, more saturated and more dyn...

2026-08-19 • Psychedelics Today

Horizons: Perspectives on Psychedelics

Please join us this autumn for the 19th Horizons conference on October 15-17 in New York City. This is one of the important annual gatherings for the field of psychedelics, and best chances to meet old friends and new...

2026-08-19 • The Conversation (Psychedelics)

New research shows how psychedelics reorganise the patterns in your brain

Brains scans show a signature linked to a dissolved separation between the self and the world.